TARGAZYME, INC.
Biotech · Private
Engineered regulatory T cells treated with TZ101 enzyme and substrate to enhance homing and engraftment for preventing graft-versus-host disease in stem cell transplants
targazyme.com →- Grants
- $2.0M
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 17
- 1 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD | $1,526,626 | |
| Federal grant | Department of Health and Human Services · Phase II · A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD | $467,137 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3217 | MULTITARGA LLC | — | — |
| 3218 | Shield Pharma LLC | — | — |
| 3219 | QWIXEL THERAPEUTICS, LLC | — | — |
| 3220 | TARGAZYME, INC. | — | — |
| 3221 | Rondo Therapeutics | — | — |
| 3222 | GROW BIOMEDICINE LLC | — | — |
| 3223 | VELUM INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Systems For Combinatorial Therapies Containing Fucosylated Cells And Immune Checkpoint Inhibitors And Methods Of Production And Use Thereofapplication
- Augmentation Of Cell Therapy Efficacy Including Treatment With Alpha, 1,3 Fucosyltransferaseapplication
- Augmentation Of Cell Therapy Efficacy Including Treatment With Alpha 1,3 Fucosyltransferaseapplication
- Augmentation of Cell Therapy Efficacy Including Treatment with Alpha 1,3 Fucosyltransferasegranted
- Manufacture And Cryopreservation Of Fucosylated Cells For Therapeutic Useapplication
- Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Useapplication
- Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Useapplication
- Augmentation of Cell Therapy Efficacy Including Treatment With Alpha 1,3 Fucosyltransferaseapplication
- Augmentation Of Cell Therapy Efficacy Including Treatment With Alpha 1-3 Fucoslytransferaseapplication
- Compositions And Systems For Combinatorial Therapies Containing Fucosylated Cells And Immune Checkpoint Inhibitors And Methods Of Production And Use Thereofapplication
- Compositions And Systems For Combinatorial Therapies Containing Fucosylated Stem Cells And Hematopoietic Enhancers And/or Immunotherapeutics And Methods Of Production And Use Thereofapplication
- Compositions And Systems For Combinatorial Therapies Containing Fucosylated Cells And Immune Checkpoint Inhibitors And Methods Of Production And Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.